
Savara Inc. Highlights Long-Term IMPALA-2 Phase 3 Data for Molgramostim in aPAP
Savara Inc. Reports Sustained Efficacy and Favorable Safety Findings from the Ongoing IMPALA-2 Phase 3 Open-Label Extension Study of Molgramostim in aPAP Patients Savara Inc. announced the presentation of new…












